Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines

BACKGROUND: Approximately 80% of patients with osteosarcoma harbor subclinical pulmonary micrometastases at diagnosis. Conventional chemotherapy includes methotrexate, doxorubicin, and cisplatin (MAP); however, this regimen and thus overall survival (60%-70%) have remained largely unchanged for 30 y...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Orthop Relat Res
Main Authors: Collier, Christopher D., Wirtz, Emily C., Knafler, Gabrielle J., Morris, William Z., Getty, Patrick J., Greenfield, Edward M.
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer 2018
Teme:
Regular Features
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437591/
https://ncbi.nlm.nih.gov/pubmed/29481344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11999.0000000000000059
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki